Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

医学奥拉帕尼 BRCA突变内科学临床终点肿瘤科安慰剂卵巢癌无进展生存期 PARP抑制剂随机对照试验癌症化疗病理生物化学化学替代医学聚合酶聚ADP核糖聚合酶基因

作者

Andrés Poveda,Anne Floquet,Jonathan A. Ledermann,Rebecca Asher,Richard T. Penson,Amit M. Oza,Jacob Korach,Tomasz Huzarski,Sandro Pignata,Michael Friedlander,Alessandra Baldoni,Tjoung-Won Park-Simon,Kenji Tamura,Gabe S. Sonke,Alla Lisyanskaya,Jae‐Hoon Kim,Elias Abdo Filho,Tsveta Milenkova,Elizabeth Lowe,Philip Rowe,Ignace Vergote,Éric Pujade-Lauraine,Jacob Korach,Tomasz Huzarski,Tomasz Byrski,Patricia Pautier,Michael Friedlander,Philipp Harter,Nicoletta Colombo,Sandro Pignata,Giovanni Scambia,Maria Ornella Nicoletto,Fiona Nussey,Andrew R. Clamp,Richard T. Penson,Amit M. Oza,A. Poveda Velasco,Manuel Rodrigues,Jean‐Pierre Lotz,Frédèric Selle,Isabelle Ray‐Coquard,Diane Provencher,Aleix Prat Aparicio,Laura Vidal Boixader,Clare L. Scott,Kenji Tamura,Mayu Yunokawa,Alla Lisyanskaya,Jacques Médioni,Nicolas Pécuchet,Coraline Dubot,Thibault De La Motte Rouge,Marie‐Christine Kaminsky,B. Weber,Alain Lortholary,Christine Parkinson,Jonathan A. Ledermann,Sarah Williams,Susana Banerjee,Jonathan A. Cosin,James Hoffman,Richard T. Penson,Marie Plante,Allan Covens,Gabe S. Sonke,Florence Joly,Anne Floquet,Susana Banerjee,Holger W. Hirte,Amnon Amit,Tjoung-Won Park-Simon,Koji Matsumoto,Sergei Tjulandin,Jae‐Hoon Kim,Laurence Gladieff,Roberto Sabbatini,David M. O’Malley,Patrick Timmins,Daniel Kredentser,Nuria Laínez Milagro,M.P. Barretina Ginesta,Ariadna Tibau Martorell,Alfonso Gómez De Liaño Lista,Belén Ojeda González,Linda Mileshkin,Masaki Mandai,Ingrid Boere,Petronella B. Ottevanger,Joo‐Hyun Nam,Elias Abdo Filho,Salima Hamizi,Francesco Cognetti,David Warshal,Elizabeth Dickson-Michelson,Scott Kamelle,Nathalie D. McKenzie,Gustavo C. Rodriguez,Deborah K. Armstrong,Eva Chalas,Paul Celano,Kian Behbakht,Susan A. Davidson,Stephen Welch,Limor Helpman,Ami Fishman,Ilan Bruchim,Magdalena Sikorska,Anna Słowińska,Wojciech Rogowski,Mariusz Bidziński,Beata Śpiewankiewicz,Antonio Casado,César Mendiola Fernández,Martina Gropp‐Meier,Toshiaki Saito,Kazuhiro Takehara,Takayuki Enomoto,Hidemichi Watari,Chel Hun Choi,Byoung‐Gie Kim,Jae‐Weon Kim,Roberto Hegg,Ignace Vergote

出处

期刊：Lancet Oncology [Elsevier BV]
日期：2021-03-20 卷期号：22 (5): 620-631 被引量：311

链接

ac.uk ac.uk ac.uk ac.uk nih.govdoi.org

标识

DOI：10.1016/s1470-2045(21)00073-5

摘要

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously been shown to extend progression-free survival versus placebo when given to patients with relapsed high-grade serous or endometrioid ovarian cancer who were platinum sensitive and who had a BRCA1 or BRCA2 (BRCA1/2) mutation, as part of the SOLO2/ENGOT-Ov21 trial. The aim of this final analysis is to investigate the effect of olaparib on overall survival.

求助该文献

最长约 10秒，即可获得该文献文件

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial

今日热心研友